CMAJ • June 6, 2006; 174 (12). doi:10.1503/cmaj.060110.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow Online Appendix
Right arrow Correction (v176,p976)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, N.
Right arrow Articles by McAlister, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, N.
Right arrow Articles by McAlister, F. A.
Related Collections
Right arrow Drugs: cardiovascular system

Re-examining the efficacy of ß-blockers for the treatment of hypertension: a meta-analysis

Nadia Khan and Finlay A. McAlister

From the Division of General Internal Medicine, University of British Columbia (Khan),Vancouver, BC, and the Division of General Internal Medicine, University of Alberta (McAlister), Edmonton, Alta.


Figure 120
View larger version (20K):

[in a new window]
  		Fig. 1: Risk ratios for the composite outcome (death, stroke or myocardial infarction) for (A) patients less than 60 years of age and (B) patients 60 years of age and older receiving ß-blockers or placebo. The size of the boxes represents the number of participants who experienced a cardiovascular event. The mean age of trial participants is given in parentheses after each trial acronym. Trials are listed in order of publication. CI = confidence interval.

 

Figure 220
View larger version (24K):

[in a new window]
  		Fig. 2: Risk ratios for the composite outcome (death, stroke or myocardial infarction) for (A) patients less than 60 years of age and (B) patients 60 years of age and older receiving ß-blockers or other antihypertensive drugs. The size of the boxes represents the number of participants who experienced a cardiovascular event. The mean age of trial participants is given in parentheses after each trial acronym. Trials are listed in order of publication. CI = confidence interval.